Research
Experimental GLS-1 inhibitor demonstrates antitumor activity in advanced treatment-resistant ovarian cancer
The Brief
- A Phase I trial tested the experimental GLS-1 inhibitor IACS-6274 combined with bevacizumab and paclitaxel chemotherapy in patients with advanced platinum-resistant ovarian cancer.
- Researchers presenting the new results reported promising antitumor activity for the combination.
Why it matters
Early-phase signals of activity for a GLS-1 inhibitor combination in treatment-resistant ovarian cancer are relevant to researchers following metabolic approaches to cancer therapy.
Who’s affected
- oncology researchers
- clinicians and patients with platinum-resistant ovarian cancer
- #ovarian cancer
- #glutaminase inhibitor
- #clinical trial
- #cancer therapy
- #drug combination
Combining the experimental therapy IACS-6274 with targeted therapy bevacizumab and paclitaxel chemotherapy showed promising antitumor activity in a Phase I trial of patients with advanced platinum-resistant ovarian cancer, according to new results presented by researchers from…